ResMed announced at the ESC Congress 2013 that SERVE-HF has completed enrollment.1 SERVE-HF is an international, randomised study of 1,325 participants investigating if the treatment of central sleep-disordered breathing (central sleep apnea) improves survival and outcomes of patients with stable heart failure.

In an independent study presented during the North American Spine Society (NASS) Annual Meeting in October 2012, GE Healthcare’s OEC Elite 9900 mobile C-arm was rated the best in image quality and dose management.

Aggredyne Inc., has received ISO 13485 certification for its quality control program related to the manufacture of the AggreGuide family of platelet function analyzers.

TeraRecon announced positive ratings in the recently released KLAS 2013 Advanced Visualization performance report entitled “Advanced Visualization 2013: How Advanced Is It?” TeraRecon’s general performance ratings were particularly noteworthy, in that the company received the top scores for the following general indicators:

OrbusNeich Medical Inc. and Boston Scientific Corp. have settled all stent-related litigation between the companies.

Corindus Vascular Robotics announced the PRECISION Registry, an ongoing study aimed at collecting data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices. Giora Weisz, associate professor of Medicine at Columbia University Medical Center, will lead the study.

Boston Scientific reported favorable six-month results from the first 60 patients enrolled in the REPRISE II clinical trial evaluating the safety and performance of the Lotus Valve System in symptomatic patients with severe aortic stenosis considered at high risk for surgical valve replacement.

Decision Resources forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism (VTE) markets. Xarelto benefits from its first-to-market advantage for VTE treatment/secondary prophylaxis, the removal of the need for bridging with a low-molecular-weight heparin in the VTE treatment/secondary prophylaxis setting and once-daily dosing. Bristol-Myers Squibb/Pfizer's Eliquis will be Xarelto's closest competitor, but its later launch in both the VTE primary prophylaxis and VTE treatment/secondary prophylaxis markets, as well as its twice-daily dosing, will likely limit its sales relative to Xarelto during the 2012 to 2022 forecast period.